The London-based Supreme Court found that Actavis products infringe Eli Lilly patents for its third best-selling drug, Alimta.
The court ruled that Activis generic pemetrexed products violated Lilly’s patent for pemetrexed disodium-based cancer treatment in the UK, France, Italy and Spain prior to June 2021.
Actavis, now owned by Teva, launched its pemetrexed Armisarte in June 2015.
Read the Bloomberg coverage
